Back |
home / stock / blrx / blrx message board
Subject | By | Source | When |
---|---|---|---|
BooDog: Started to eat away at some of the long term resistance. Excellent day. Did take some off in | BooDog | investorshangout | 10/04/2018 8:07:05 PM |
znewcar1: 18% 3.6M C1.34 solid vol. mid run up Float 108,083,426 | znewcar1 | investorshangout | 10/03/2018 8:08:36 PM |
BooDog: Needs to get back over the $ to regain compliance. | BooDog | investorshangout | 08/07/2018 11:36:15 AM |
BooDog: BLRX just may start waking up. http://ir.biolinerx.com/phoenix.zhtml?c=208785&p=irol-newsArt | BooDog | investorshangout | 08/07/2018 11:11:50 AM |
PoemStone: $BLRX new volume at breakout | PoemStone | investorshangout | 02/17/2017 1:04:59 AM |
chemist823: BLRX Phase 2 initiated. BioLineRx Announces Initiation of Immuno-Oncology Phase 2 Study | chemist823 | investorshangout | 01/17/2017 12:07:43 PM |
chemist823: BLRX beginning to shape up! Pipeline expanded and data looking good. | chemist823 | investorshangout | 01/07/2017 3:59:00 PM |
News, Short Squeeze, Breakout and More Instantly...
BioLineRx Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell (HSC) Mobilization For Gene Therapy Applications in Sickle Cell Disease (SCD) PR Newswire - Investigator-initiated study in...
Orkla ASA ADR (ORKLY) is expected to report for Q1 2024 Cosmos Health Inc. (COSM) is expected to report $-0.14 for Q1 2024 Basilea Pharmaceutica AG Registered Shares (BPMUF) is expected to report for Q1 2024 DCC Plc (DCCPF) is expected to report for Q4 2024 Datatec Ltd ADR (DTTLY)...
BioLineRx Announces Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC) at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting PR Newswire New analysis of biopsy samples demonstrate...